Description:
Mitochondrial diseases are broad, they range from metabolic disorders to Huntington's diseases, Alzheimer's diseases, Parkinson's disease and schizophrenia. It is known that excessive mitochondrial division can contribute to apoptosis and therefore mitochondrial division inhibitors are an attractive therapeutic.
Mitochondrial division inhibitor 1 (Mdivi-1) is known to inhibit mitochondrial division by blocking dynamin GTPase activity. Mdivi-1 is only soluble in dimethyl sulfoxide, this limits its use in animals and humans.
This technology is a modified Mdivi-1 that is soluble in water. The modified Mdivi-1 can be useful in clinical applications of mitochondrial human diseases. In addition, the modified Mdivi-1 enhances antioxidant/anti-inflammatory properties.
Reference Number
D-1294
Market Applications
- Pharmaceutical
- Mitochondrial ageing disorders
- Anti-inflammatory properties
Features, Benenfits & Advantages
- Water soluble mdivi-1
- Phenolic group containing mdivi-1
Intellectual Property
A U.S. Provisional Patent application, Serial 62/655,677 was filed on 4/10/2018
Developmental Stage:
Structure is currently being tested in cell culture disease models
Researchers:
Reddy P. Hemmachandra, Executive Director, Garrison Institute on Aging, Lubbock, Texas.
Kuruv Chandra Sekhar, Postdoctoral Fellow, Garrison Institute on Aging, Lubbock, Texas.
Keywords:
Water soluble mdivi-1, mitochondrial ageing disorders, mitochondrial division inhibitor, antioxidant/anti-inflammatory mdivi-1.